Functional Characteristics and Regulated Expression of Alternatively Spliced Tissue Factor: An Update
| Autor: | Clayton S. Lewis, Vladimir Y. Bogdanov, Kateryna Matiash |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Gene isoform
Cancer Research biology Angiogenesis Alternative splicing Integrin pancreatic ductal adenocarcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens Review Primary transcript tissue factor Frameshift mutation Cell biology Tissue factor Exon alternative splicing breast cancer Oncology biology.protein integrins biomarker anti-cancer biologics RC254-282 |
| Zdroj: | Cancers, Vol 13, Iss 4652, p 4652 (2021) Cancers |
| ISSN: | 2072-6694 |
| Popis: | Simple Summary Alternatively spliced tissue factor (asTF) is a naturally occurring isoform of tissue factor (TF) generated via the omission of exon 5 during the processing of TF’s primary transcript. In human and mouse, asTF protein features a unique C-terminus that lacks a transmembrane domain, rendering it soluble. asTF protein is able to associate with a subset on integrins on cell surfaces, which can trigger outside-in signaling programs in a variety of cell types. In this review, we discuss recent findings on asTF’s proto-oncogenic effects, regulatory mechanisms enabling asTF’s biosynthesis, and asTF’s potential as a biomarker and therapeutic target. Abstract In human and mouse, alternative splicing of tissue factor’s primary transcript yields two mRNA species: one features all six TF exons and encodes full-length tissue factor (flTF), and the other lacks exon 5 and encodes alternatively spliced tissue factor (asTF). flTF, which is oftentimes referred to as “TF”, is an integral membrane glycoprotein due to the presence of an alpha-helical domain in its C-terminus, while asTF is soluble due to the frameshift resulting from the joining of exon 4 directly to exon 6. In this review, we focus on asTF—the more recently discovered isoform of TF that appears to significantly contribute to the pathobiology of several solid malignancies. There is currently a consensus in the field that asTF, while dispensable to normal hemostasis, can activate a subset of integrins on benign and malignant cells and promote outside-in signaling eliciting angiogenesis; cancer cell proliferation, migration, and invasion; and monocyte recruitment. We provide a general overview of the pioneering, as well as more recent, asTF research; discuss the current concepts of how asTF contributes to cancer progression; and open a conversation about the emerging utility of asTF as a biomarker and a therapeutic target. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|